29-SEP-2025 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 N 0 Screening 1420 1448 113 0 0 0 0 08/13/2019 26 5
            1448 113 0 0 0 0      
 
    2 Y 1 Lenalidomide   674 60 5 0 0 0 08/13/2019    
        2 Lenalidomide + Daratumumab   664 56 5 1 0 0      
            1338 116 10 1 0 0      
 
    3 Y 3 Stop vs Continue Treatment   275 68 21 2 0 0 08/13/2019    
            275 68 21 2 0 0      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 92 9 7 3 1 0 0 01/05/2022 109 28
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   9 6 4 3 1 0      
            19 13 7 4 1 0      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 33 20 8 4 2 0 10/12/2023 258 82
        2 DRD-R   34 19 9 5 0 0      
        3 DRD-DR   32 19 10 6 1 0      
            99 58 27 15 3 0      
 
  S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Y 0 Induction 338 23 19 12 9 3 0 07/01/2024 149 45
            23 19 12 9 3 0      
 
    2 Y 1 Dara-VCD   5 5 3 1 1 0 07/01/2024    
        2 Melphalan + ASCT   4 4 2 0 0 0      
            9 9 5 1 1 0      
 
    3 Y 3 Dara   2 2 1 1 0 0 07/01/2024    
            2 2 1 1 0 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   61 12 8 5 2 0 05/27/2021 229 80
            61 12 8 5 2 0      
 
    1 E Total Registrations   44 8 7 3 1 0 05/27/2021    
            44 8 7 3 1 0      
 
    2 E Total Registrations   31 7 2 1 0 0 05/27/2021    
            31 7 2 1 0 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   80 8 5 3 0 0 01/08/2020 252 101
            80 8 5 3 0 0      
 
    1 E Total Registrations   39 5 2 2 0 0 01/08/2020    
            39 5 2 2 0 0      
 

29-SEP-2025 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 109 28